Zynex Inc. (ZYXI)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Zynex Medical offers non-invasive and non-addictive pain solution NexWave - ICYMI
Zynex Inc (NASDAQ:ZYXI) executive vice president of sales Steve Fox talked with Proactive about the company's mission to provide noninvasive, non-addictive at-home pain management options through its flagship device, NexWave. Fox discussed how Zynex Medical is addressing the opioid crisis by offering alternative pain solutions that empower both healthcare providers and patients.
Zynex's Sell-Off Creates A Speculative Buying Opportunity
Zynex, Inc. specializes in non-invasive pain management and patient monitoring, with promising advancements like the NiCO pulse oximeter targeting accurate readings for diverse skin tones. Despite disappointing Q4 2024 results and reimbursement challenges, Zynex aims for long-term growth with cost-cutting measures and a strategic market entry plan for NiCO. Valuation concerns arise from high current P/E ratios, but projected forward P/E compression suggests potential deep-value in the growing medical device market.
Zynex, Inc. (ZYXI) Q4 2024 Earnings Call Transcript
Zynex, Inc. (NASDAQ:ZYXI ) Q4 2024 Earnings Conference Call March 11, 2025 4:15 PM ET Company Participants Brian Prenoveau - Investor Relations Thomas Sandgaard - Chairman of the Board, President, and Chief Executive Officer Dan Moorhead - Chief Financial Officer Anna Lucsok - Chief Operating Officer Donald Gregg - President, Zynex Monitoring Solutions Conference Call Participants Jeffrey Cohen - Ladenburg Yi Chen - H.C. Wainwright & Co. Operator Good afternoon, ladies and gentlemen, and welcome to the Zynex Fourth Quarter 2024 Earnings Conference Call.
Zynex Inc. (ZYXI) Reports Q4 Loss, Misses Revenue Estimates
Zynex Inc. (ZYXI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.09. This compares to earnings of $0.04 per share a year ago.
Zynex delivers solid growth with rising orders and expanding product innovation
Zynex Inc (NASDAQ:ZYXI) has reported its financial results for the fourth quarter and the full year 2024, with full-year revenue growing 4% to reach $192.4 million. The medical technology company specializing in non-invasive devices for pain management, rehabilitation and patient monitoring saw 16% year-over-year growth in orders in 2024.
Zynex COO on pain management innovations and growth plans – ICYMI
Zynex Inc (NASDAQ:ZYXI) COO Anna Lucsok shared insights earlier this week about the company's operational strategies and future growth plans in an interview with Proactive. Lucsok discussed the company's strong performance in sales and reimbursement, as well as its mission to provide non-opioid pain management solutions.
Zynex eyes FDA submission for NiCO oximeter as it expands portfolio of innovative medical devices
Zynex Inc (NASDAQ:ZYXI) continues to expand its portfolio of innovative, non-invasive medical devices targeting pain management, rehabilitation, and pain monitoring. The company's flagship NexWave product is a multi-modality electrotherapy device that combines various therapeutic modalities to provide effective pain relief.
Zynex partners with VA to offer pain management solutions for veterans
Zynex Inc (NASDAQ:ZYXI) has announced a new partnership with Veterans Affairs Medical Centers (VAMCs) across the United States, a significant opportunity to expand the reach of its noninvasive medical devices for pain management and rehabilitation. This collaboration provides an opportunity to expand sales of Zynex's pain management solutions within the largest healthcare network in the US, which serves over 9 million enrolled veterans annually and accounts for more than $112 billion in annual healthcare spending.
Zynex CEO outlines plans for 2025 after revenue milestone – ICYMI
Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard spoke with Proactive about the company's 2024 achievements and plans for 2025. Zynex reached $200 million in revenue while staying profitable, thanks to employee dedication and innovative pain management products like braces and cold therapy devices.
ZYXI Stock Gains on the Completion of NiCO's Clinical Verification Trial
Zynex announces the completion of the clinical verification trial of its NiCO pulse oximeter.
Zynex joins Open Oximetry Project as it advances innovative NiCO pulse oximeter
Zynex Inc (NASDAQ:ZYXI) has announced its membership in the Collaborative Community of the Open Oximetry Project as an industry member. This initiative, led by the University of California, San Francisco's Center for Health Equity in Surgery and Anesthesia, aims to enhance the safety and accuracy of pulse oximeters across diverse populations.
Zynex leverages multi-modality NexWave device to transform pain management
Zynex Inc (NASDAQ:ZYXI) holds a competitive niche in the pain management market, benefiting from its focus on non-invasive, reimbursable solutions. While the company has successfully capitalized on the growing demand for non-opioid therapies, staying ahead will depend on its ability to innovate and adapt to a rapidly evolving medical device landscape.
